SAB Biotherapeutics Announces Presentations at EASD Meeting
SAB Biotherapeutics, Inc. (NASDAQ: SABS), a pioneering clinical-stage biopharmaceutical company, is set to make significant waves at the upcoming Annual Meeting of the European Association for the Study of Diabetes (EASD). The event, scheduled from September 15 to September 19, 2025, will be held at the prestigious VIECON - Vienna Congress & Convention Center. SAB BIO will present groundbreaking findings related to their cutting-edge immunotherapy, SAB-142, aimed at addressing autoimmune type 1 diabetes (T1D).
Overview of Presentations
During the EASD Annual Meeting, SAB Biotherapeutics plans to deliver five comprehensive presentations, which include four impactful oral talks as well as a symposium that will be hosted by INNODIA. These presentations represent the company’s commitment to advancing therapy for individuals affected by T1D.
Illuminating Key Research Topics
The focus of the presentations will be centered around the innovative aspects of SAB-142, which serves as a fully human anti-thymocyte immunoglobulin developed to modify the disease process in T1D. These findings promise to deliver hope and potential for changing lives through disease-modifying therapies.
Symposium Highlight: Life-Changing T1D Therapies
One of the key events will be an INNODIA-hosted symposium titled "Life-Changing T1D Therapies Symposium," to be led by Alexandra Kropotova, MD, MBA, the Executive Vice President and Chief Medical Officer of SAB BIO. The symposium aims to foster discussion on transforming T1D care strategies through unique therapeutic approaches, scheduled for Monday, September 15, 2025, from 16:40 to 20:00 CEST in Lima Hall.
Key Presentation Topics
The scheduled presentations include:
- Immunomodulation Without Sustained Lymphodepletion: An exploration of SAB-142 as a fully human anti-thymocyte globulin will take place on September 16, 2025, at 10:00 CEST in Mumbai Hall. Presenting will be Alexandra Kropotova.
- Mechanism of Action: Christoph Bausch, PhD, Executive Vice President and Chief Operating Officer, will delve into how SAB-142 functions in treating type 1 diabetes on September 18, 2025, from 10:45 CEST in Sofia Hall.
- Novel Pharmacokinetic Assay: Conducted by Eric Sandhurst, PhD, Director of Program Management, this presentation will introduce a new method for measuring SAB-142's efficacy on September 18, 2025, at 14:00 CEST in Station 03, Hall C.
- Specimen Quality for Multicenter Clinical Trials: Also presented by Eric Sandhurst, comparisons of blood preservation methods will take place on September 18, 2025, at 14:00 CEST in Station 03, Hall C.
About EASD Annual Meeting
The EASD Annual Meeting is renowned for being the largest diabetes conference globally, attracting thousands of healthcare professionals and researchers focused on diabetes. In this vibrant setting, key research findings and clinical studies to improve treatment modalities are showcased, making it an essential event for healthcare advancement.
About SAB Biotherapeutics
SAB Biotherapeutics is revolutionizing treatment options for immune and autoimmune conditions through the development of human, multi-specific, high-potency immunoglobulins without relying on human donors or convalescent plasma. Their flagship compound, SAB-142, promises to reshape diabetes treatment paradigms by potentially halting disease progression through advanced therapeutic techniques.
CONTACT
Investor Relations: Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com
Media Inquiries: Sheila Carlson, SAB BIO, scarlson@sab.bio
Frequently Asked Questions
What is SAB-142?
SAB-142 is a fully human anti-thymocyte immunoglobulin designed to modify the autoimmune responses in type 1 diabetes.
When will the EASD Annual Meeting take place?
The EASD Annual Meeting is scheduled from September 15 to 19, 2025.
Who will present at the INNODIA-hosted symposium?
Alexandra Kropotova, MD, MBA, will present at the INNODIA-hosted symposium.
What other topics will be covered in the presentations?
Topics include immunomodulation, mechanism of action of SAB-142, and novel methods for clinical trials.
How does SAB BIO differ from other biopharmaceutical companies?
SAB BIO focuses on developing therapies without the need for donors or plasma, leveraging transchromosomic technology for sustainable drug production.
